File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Predictors for relapse in a double-blind randomized placebo-controlled discontinuation study of remitted first-episode psychosis patients

TitlePredictors for relapse in a double-blind randomized placebo-controlled discontinuation study of remitted first-episode psychosis patients
Authors
Issue Date2008
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/schres
Citation
The 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders, Montreux, Switzerland, 3–7 February 2008. In Schizophrenia Research, 2008, v. 98 suppl., p. 13 How to Cite?
AbstractBackground: Clinical decisions about relapse prevention and maintenance therapy following a first/single psychotic episode can be enhanced if features that predict higher relapse risk can be identified. While naturalistic studies suggest that maintenance medication reduces relapse risks, it is important that other risk factors controlling for medication status can also be identified. Methods: Potential demographic, clinical and cognitive predictors for relapse were measured at the beginning of a double-blind randomized placebo-controlled study. Following a first/single episode with DSM-IV schizophrenia and related psychoses, remitted patients who had remained well on maintenance medication for at least 1 year were randomized to receive either maintenance therapy (with quetiapine 400 mg/day), or placebo for 12 months. Results: 178 patients were randomized. Relapse rates were 35% (31/89) in maintenance group and 66% (59/89) in placebo group. Potential predictors were initially identified in univariate Cox regression models (p < 0.1) and were subsequently entered into a multivariate Cox regression model for measuring the relapse risk. Significant predictors included patients on placebo (hazard ratio = 0.388, CI = 0.235–0.641; p < 0.001); having more pre-morbid schizotypal traits (hazard ratio = 2.37, CI = 1.364–4.116; p = 0.002); scoring lower in the logical memory test (hazard ratio = 0.944, CI = 0.897–0.994; p = 0.028); and having more soft neurological signs (disinhibition) (hazard ratio = 1.305, CI = 0.996–1.709; p = 0.053). Conclusions: Relapse predictors identified in this study may help to inform clinical decisions about discontinuation of maintenance therapy specifically for patients with a first/single episode psychosis following at least 1 year of maintenance therapy. Acknowledgement: We are grateful to Dr TJ Yao at the Clinical Trials Center, University of Hong Kong, for statistical advice. The study was supported by investigator initiated trial award from AstraZeneca and the Research Grants Council Hong Kong (Project number: 765505).
Persistent Identifierhttp://hdl.handle.net/10722/81564
ISSN
2015 Impact Factor: 4.453
2015 SCImago Journal Rankings: 2.304

 

DC FieldValueLanguage
dc.contributor.authorHui, CLMen_HK
dc.contributor.authorChen, EYHen_HK
dc.contributor.authorLam, Men_HK
dc.contributor.authorLaw, CWen_HK
dc.contributor.authorChiu, CPYen_HK
dc.contributor.authorChung, DWSen_HK
dc.contributor.authorTso, Sen_HK
dc.contributor.authorPang, EPFen_HK
dc.contributor.authorChan, KTen_HK
dc.contributor.authorWong, YCen_HK
dc.contributor.authorMo, Fen_HK
dc.contributor.authorChan, KPMen_HK
dc.contributor.authorHung, SFen_HK
dc.contributor.authorHoner, WGen_HK
dc.date.accessioned2010-09-06T08:19:19Z-
dc.date.available2010-09-06T08:19:19Z-
dc.date.issued2008en_HK
dc.identifier.citationThe 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders, Montreux, Switzerland, 3–7 February 2008. In Schizophrenia Research, 2008, v. 98 suppl., p. 13en_HK
dc.identifier.issn0920-9964en_HK
dc.identifier.urihttp://hdl.handle.net/10722/81564-
dc.description.abstractBackground: Clinical decisions about relapse prevention and maintenance therapy following a first/single psychotic episode can be enhanced if features that predict higher relapse risk can be identified. While naturalistic studies suggest that maintenance medication reduces relapse risks, it is important that other risk factors controlling for medication status can also be identified. Methods: Potential demographic, clinical and cognitive predictors for relapse were measured at the beginning of a double-blind randomized placebo-controlled study. Following a first/single episode with DSM-IV schizophrenia and related psychoses, remitted patients who had remained well on maintenance medication for at least 1 year were randomized to receive either maintenance therapy (with quetiapine 400 mg/day), or placebo for 12 months. Results: 178 patients were randomized. Relapse rates were 35% (31/89) in maintenance group and 66% (59/89) in placebo group. Potential predictors were initially identified in univariate Cox regression models (p < 0.1) and were subsequently entered into a multivariate Cox regression model for measuring the relapse risk. Significant predictors included patients on placebo (hazard ratio = 0.388, CI = 0.235–0.641; p < 0.001); having more pre-morbid schizotypal traits (hazard ratio = 2.37, CI = 1.364–4.116; p = 0.002); scoring lower in the logical memory test (hazard ratio = 0.944, CI = 0.897–0.994; p = 0.028); and having more soft neurological signs (disinhibition) (hazard ratio = 1.305, CI = 0.996–1.709; p = 0.053). Conclusions: Relapse predictors identified in this study may help to inform clinical decisions about discontinuation of maintenance therapy specifically for patients with a first/single episode psychosis following at least 1 year of maintenance therapy. Acknowledgement: We are grateful to Dr TJ Yao at the Clinical Trials Center, University of Hong Kong, for statistical advice. The study was supported by investigator initiated trial award from AstraZeneca and the Research Grants Council Hong Kong (Project number: 765505).-
dc.languageengen_HK
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/schresen_HK
dc.relation.ispartofSchizophrenia Researchen_HK
dc.rightsNOTICE: this is the author’s version of a work that was accepted for publication in Schizophrenia Research. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Schizophrenia Research, [VOL 98, ISSUE Supplement, 2008] DOI 10.1016/j.schres.2007.12.023en_HK
dc.titlePredictors for relapse in a double-blind randomized placebo-controlled discontinuation study of remitted first-episode psychosis patientsen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailHui, CLM: h0007716@graduate.hku.hken_HK
dc.identifier.emailChen, EYH: eyhchen@hku.hken_HK
dc.identifier.emailLaw, CW: lawcw@HKUCC.hku.hken_HK
dc.identifier.emailChiu, CPY: chiupyc@hkucc.hku.hk, cindychiu@gmail.comen_HK
dc.identifier.authorityChen, EYH=rp00392en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.schres.2007.12.023-
dc.identifier.hkuros142191en_HK
dc.identifier.hkuros143564-
dc.identifier.volume98-
dc.identifier.issuesuppl.-
dc.identifier.spage13-
dc.identifier.epage13-
dc.publisher.placeNetherlands-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats